Fidrisertib

Overview

Fidrisertib (BLU-782) is the orally active inhibitor for activin receptor-like kinase 2 ( ALK2 ) that inhibits ALK2 R206H , ALK2 , ALK1 , ALK6 , ALK3 , ALK4 , TGFβR2 and ALK5 with IC 50 s of 0.2, 0.6, 3, 24, 45, 65, 67 and 155 nM, respectively.

Application

Products | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lipid Metabolism | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-β Receptor

Product Information

• Catalog No.: HY-117887
• CAS No.: 2141955-96-4
• Molecular Formula: C31H42N6O4
• Molecular Weight: 562.70
• Purity: 98.58%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source